Loading patent…
OwnerDavid Gordon Bermudesinventor
Estimating the term…
A substantially purified substance having the properties of a bacterial microcin methionine analog, methionine synthesis inhibitor, tRNA-methionine synthase inhibitors or methionine competitive inhibitor capable of inhibiting tumor cell growth without inhibiting the growth of normal cells or treating neoplastic diseases, and may be used alone or in combination with other anti-cancer agents. The purified substance may also have anti-hyperhomocysteineuria and/or anti-infective properties, such as antifungal activity. The purified substance can be safely administered to animals including humans for the treatment of neoplastic, hyperhomocysteinemia and/or infectious diseases for the treatment of those diseases.
A method of treating an animal, comprising administering an effective dose of at least one substantially purified, pharmaceutically acceptable microcin methionine analogue or microcin methionine synthesis inhibitor except microcin 15m or microcin M15 or a microcin from E. coli LP15, to an animal having at least one of a tumor, hyperhomocysteinemia, and an infectious disease, in an effective amount to thereby respectively inhibit tumor growth, treat hyperhomocysteinemia, or treat the infectious disease.
A method of treating an animal, comprising:
A pharmaceutical composition for administration to a human having a neoplasm, comprising at least one pharmaceutically acceptable agent selected from the group consisting of microcin methionine analogues and microcin methionine synthesis inhibitors except microcin 15m or microcin M15 or a microcin from E. coli LP15, which has been substantially purified, in a sterile unit dose form selected from the group consisting of an intravenous dosage vial, an oral unit dosage form, and a parenteral dosage form, in an amount sufficient to achieve significant retardation in tumor growth and within a maximum tolerated dose, which is diluted with or compounded with at least one other active or inactive ingredient.
Dependencies are inferred from the claim text.